Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India · Delayed Price · Currency is INR 212.50
+1.91 (0.91%)
Nov 12, 2026, 3:30 PM IST
NSE:SPARC Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 68,961 | 37,284 | 48,000 | 119,521 | 58,203 | 80,734 | |
Market Cap Growth | 62.10% | -22.32% | -59.84% | 105.35% | -27.91% | 116.74% |
Enterprise Value | 56,005 | 41,441 | 48,951 | 116,002 | 60,088 | 81,455 |
Last Close Price | 212.35 | 114.89 | 147.91 | 368.30 | 179.35 | 296.95 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 4.22 | 2.40 | - | - | - | - |
Forward PE | - | 91.22 | 91.22 | 91.22 | 91.22 | 91.22 |
PS Ratio | 3.57 | 1.98 | 66.88 | 158.21 | 24.38 | 58.82 |
PB Ratio | 4.78 | 2.79 | -22.12 | 95.04 | 11.35 | 258.55 |
P/TBV Ratio | 5.03 | 2.94 | - | 143.93 | 11.94 | 995.49 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.90 | 2.21 | 68.21 | 153.55 | 25.17 | 59.35 |
EV/EBITDA Ratio | 3.40 | 2.58 | - | - | - | - |
EV/EBIT Ratio | 3.42 | 2.59 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.00 | 0.42 | -1.24 | 0.49 | 0.03 | 2.54 |
Debt / EBITDA Ratio | 0.00 | 0.35 | - | - | - | - |
Debt / FCF Ratio | 0.00 | - | - | - | - | - |
Net Debt / Equity Ratio | -0.90 | 0.42 | -1.23 | -0.76 | -0.75 | 2.12 |
Net Debt / EBITDA Ratio | -0.79 | 0.35 | -0.82 | 0.24 | 1.80 | -0.35 |
Net Debt / FCF Ratio | -0.83 | -2.12 | -0.72 | 0.21 | 4.58 | -0.28 |
Asset Turnover | 1.94 | 1.50 | 0.17 | 0.11 | 0.43 | 0.54 |
Inventory Turnover | - | 13.41 | 17.60 | 28.64 | 26.43 | 25.15 |
Quick Ratio | 7.26 | 0.01 | 0.05 | 0.81 | 2.47 | 0.25 |
Current Ratio | 7.65 | 2.47 | 0.07 | 1.02 | 2.54 | 0.42 |
Return on Equity (ROE) | 298.10% | 276.89% | - | -121.28% | -81.83% | - |
Return on Assets (ROA) | 102.58% | 79.74% | -49.09% | -38.24% | -25.18% | -48.08% |
Return on Capital Employed (ROCE) | 109.80% | 112.90% | 863.10% | -164.60% | -34.30% | -180.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 23.69% | 41.66% | -7.14% | -3.24% | -3.82% | -2.52% |
FCF Yield | 22.61% | -7.04% | -7.72% | -3.81% | -1.45% | -2.98% |
Buyback Yield / Dilution | -0.20% | - | - | -13.99% | -8.19% | -0.42% |